Agios Pharmaceuticals said on Wednesday its drug met the main and secondary goals in a late-stage study in patients with an inherited blood disorder.
https://finance.yahoo.com/news/agios-blood-disorder-drug-meets-114036759.html
Wednesday, January 3, 2024
Invivyd Seeks Emergency Use Authorization for the Pre-exposure Preventive of COVID-19
- EUA submission is based on positive initial results from the ongoing CANOPY Phase 3 pivotal clinical trial and ongoing in vitro neutralization activity against relevant SARS-CoV-2 variants
- VYD222 demonstrates continued in vitro neutralization activity against major SARS-CoV-2 variants, including JN.1, currently the fastest growing variant in the U.S.
- Company continues preparations for potential commercial launch if EUA is granted
Collegium Provides 2024 Financial Guidance
– Product Revenues, Net Expected in the Range of $580.0 Million to $595.0 Million –
– Adjusted Operating Expenses* Expected in the Range of $120.0 Million to $125.0 Million –
– Adjusted EBITDA* Expected in the Range of $380.0 Million to $395.0 Million –
– $150.0 Million Share Repurchase Program Authorized by the Board of Directors –
NEXI Stock Fans, Mark Your Calendars for Jan. 18
- Shares of immunotherapy specialist NexImmune (NEXI) are skyrocketing on Wednesday.
- Management seeks to dissolve the company at a meeting on Jan. 18.
- A short squeeze in NEXI stock appears to have caught short traders off guard.
Inexplicably, shares of embattled immunotherapy specialist NexImmune (NASDAQ:NEXI) are skyrocketing more than 190% despite efforts to dissolve the business. An earlier attempt to vote on the liquidation and dissolution of the biotechnology enterprise failed due to a lack of quorum. Given the uncertainty over the company’s future, a short squeeze in NEXI stock may be what’s materializing today, thus catching bearish traders off guard.
On Dec. 21, 2023, NexImmune adjourned its special meeting to close the business. However, according to the accompanying Form 8-K disclosure, no business was conducted to allow time to achieve a quorum. As a result, a new meeting will take place on Jan. 18 of this year at 10:00 a.m. Eastern. Further, the format will be virtual, not in person, thus potentially facilitating greater participation.
Leading up to the special meeting, NEXI stock is drawing much attention, although not for encouraging reasons. On the first day of December, exchange operators at the Nasdaq pulled the circuit breakers on NexImmune shares. The reason code cited for the action was listed as T12, a cessation of trading “pending receipt of additional information.”
Nasdaq certainly had reason to be skeptical about the dramatic rise of NEXI stock back then. Just the month prior, management had disclosed that it laid off “substantially all” its employees.
Short Squeeze Likely Fueled the Rise of NEXI Stock
Now, recent history is repeating itself, with NEXI stock shooting up more than 190% at the time of this writing. Thanks to the surge of the meme trading phenomenon, it’s natural to assume that a short squeeze may be influencing today’s proceedings. And that may be exactly what’s going on, although the data initially presents a deceptive picture.
According to Fintel, the short interest of NEXI stock sits at 4.96% of its float. While this metric indicates bearish traders borrowing shares for shorting activities, the figure itself is relatively unremarkable. Investopedia notes that short interest above 10% is typically considered “fairly high” while anything above 20% is considered “extremely high.”
https://investorplace.com/2024/01/dear-nexi-stock-fans-mark-your-calendars-for-jan-18/
ABVC: $460M From AiBtl BioPharma in 1st Milestone Payment of Global Licensing Fees
ABVC BioPharma, Inc. (NASDAQ: ABVC) and its subsidiary BioLite, Inc. ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that the Company and its subsidiary received an aggregate of 46 million shares from AiBtl BioPharma Inc. ("AiBtl"), as its first milestone payment under a global licensing agreement. The agreement between the Company and AiBtl placed a value of $460 ($10 per share) on such payment. AiBtl is a private company, and the share value is based on the terms of the agreement between the parties and the valuation report done by an independent third party.
The Company entered into a definitive global licensing agreement with AiBtl on November 12, 2023, for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder). According to the terms of the agreement, AiBtl delivered 46M shares to the Company as the first milestone payment. The Company expects AiBtl to achieve the further milestones under the agreement, upon which the Company may receive the remaining licensing fees of up to $7M cash and 5% royalties of net sales, up to $200M.
Watch: "Guerrilla Camps" Set Up By Leftist Groups Assist Cartels In Southern Border Invasion
Real America's Voice host Ben Bergquam published a video on social media platform X that exposes what is described as a 'guerrilla camp' on the southern border, operated by radical leftist groups, which are aiding in the illegal migrant invasion by cartels.
"OK, here is the whole video. You have to watch it all - it just gets worse and worse! Leftists caught directly aiding and abetting the invasion of our country the wall in Sasabe, Arizona," Bergquam wrote on X.
He continued: " These are some of the same people that we previously exposed harboring illegals at their camp in Arivaca. How do we save our country when we allow enemies within to do this? When we take power back, these organizations must be defunded and prosecuted."
Last week, a separate report from the new website Muckraker revealed a network of NGOs, or non-governmental organizations, were playing a powerful role in coordinating the large-scale invasion of illegals at the southern border.
"A lot of NGOs are helping Biden open the border to unlimited illegal crossing. But none of this could happen without the president's approval," Byron York, the chief political correspondent at the Washington Examiner, recently said.
The Biden administration, meanwhile, has been deliberately downplaying the border crisis - which they created with a virtual invitation for migrants to pour into the country after striking down several Trump-era border protections on day one.
New data from Fox News shows a record 302,000 encounters with illegal migrants occurred in December, which marks 785,000 encounters since Oct. 1.
It appears Democrats might be funneling taxpayer funds into radical leftist groups, which are reportedly assisting cartels in America's invasion.
Verona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024 at 4:30 PM PST / 12:30 AM GMT.
A webcast of the event will be available on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.
https://www.biospace.com/article/releases/verona-pharma-to-present-at-42nd-annual-j-p-morgan-healthcare-conference/
Subscribe to:
Posts (Atom)